Shenzhen Microprofit Biotech Co., Ltd announces an agreement with NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) about the exclusive U.S. distributor of fluorecare® rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19. […]more...
To combat the 2019 novel coronavirus, Microprofit Biotech has concentrated on the research and development of rapid test kit for SARS-CoV-2. On Mar 19th, our detection kit officially obtained CE conformation. […]more...
We are very honored to announce that our Immunofluorescence Quantitative Analyzer has completed the NGSP certification. It marks the high performance and reliable character of our fluorecare® HbA1c test. […]more...
From Dec.2019 to recent days, the coronavirus disease 2019 (COVID-19) have been spreading all over the world. Under the strict control of quarantine and transmission, the outburst of COVID-19 in mainland China is already under control. Yet the transmission and growth of infected case is still increasing worldwide. […]more...
In 2019, fluorecare®, as the leading brand of Microprofit Biotech, received much support and trust from all over the world. We would like to thank every customer we contacted this year. And hope we can maintain a tight collaboration in the coming 2020 and make a bigger achievement. […]more...
Last week, Microprofit Biotech attended MEDICA, the leading international trade fair of medicine in the world. MEDICA attracted over 4,000 exhibitors from more than 60 countries every year with its indispensable influence all over the world. […]more...
Microprofit fluorecare® has continuously devoted much effort to develop new products and improve the performance of products already in the market. […]more...
Shenzhen Microprofit Biotech Co., Ltd announces an agreement with NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) about the exclusive U.S. distributor of fluorecare® rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19. […]more...
To combat the 2019 novel coronavirus, Microprofit Biotech has concentrated on the research and development of rapid test kit for SARS-CoV-2. On Mar 19th, our detection kit officially obtained CE conformation. […]more...
We are very honored to announce that our Immunofluorescence Quantitative Analyzer has completed the NGSP certification. It marks the high performance and reliable character of our fluorecare® HbA1c test. […]more...
From Dec.2019 to recent days, the coronavirus disease 2019 (COVID-19) have been spreading all over the world. Under the strict control of quarantine and transmission, the outburst of COVID-19 in mainland China is already under control. Yet the transmission and growth of infected case is still increasing worldwide. […]more...
In 2019, fluorecare®, as the leading brand of Microprofit Biotech, received much support and trust from all over the world. We would like to thank every customer we contacted this year. And hope we can maintain a tight collaboration in the coming 2020 and make a bigger achievement. […]more...
Last week, Microprofit Biotech attended MEDICA, the leading international trade fair of medicine in the world. MEDICA attracted over 4,000 exhibitors from more than 60 countries every year with its indispensable influence all over the world. […]more...
Microprofit fluorecare® has continuously devoted much effort to develop new products and improve the performance of products already in the market. […]more...